Denosumab-related osteonecrosis of the jaws

Osteoporosis International

Volumn 22, Issue 1, 2011, Pages 369-370

  Kyrgidis, A ^b   Toulis, K A ^a  

^a 424 General Army Hospital   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ZOLEDRONIC ACID;

BONE METASTASIS; CANCER PATIENT; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; JAW OSTEONECROSIS; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; HUMANS; JAW DISEASES; OSTEONECROSIS; RANK LIGAND;

EID: 77949460927     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1177-6     Document Type: Letter

References (12)

1. AD Anastasilakis KA Toulis SA Polyzos E Terpos 2009 RANKL inhibition for the management of patients with benign metabolic bone disorders Expert Opin Investig Drugs 18 1085 1102 1:CAS:528:DC%2BD1MXosFCmtbs%3D 10.1517/ 13543780903048929 19558335
2. A Kyrgidis S Triaridis K Vahtsevanos K Antoniades 2009 Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients Expert Rev Anticancer Ther 9 1125 1134 1:CAS:528:DC%2BD1MXpvF2qu7o%3D 10.1586/era.09.74 19671032
3. AD Anastasilakis KA Toulis DG Goulis SA Polyzos S Delaroudis A Giomisi E Terpos 2009 Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis Horm Metab Res 41 721 729 1:CAS:528:DC%2BD1MXhsVyrtrvM 10.1055/s-0029-1224109 19536731
4. BJ Edwards M Gounder JM McKoy I Boyd M Farrugia C Migliorati R Marx S Ruggiero M Dimopoulos DW Raisch S Singhal K Carson E Obadina S Trifilio D West J Mehta CL Bennett 2008 Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw Lancet Oncol 9 1166 1172 10.1016/S1470-2045(08)70305-X 19038763
5. RE Coleman 2008 Risks and benefits of bisphosphonates Br J Cancer 98 1736 1740 1:CAS:528:DC%2BD1cXmtlCis7c%3D 10.1038/sj.bjc.6604382 18506174
6. Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg Oct 15. doi: 10.1016/j.bjoms.2009.08.030
7. Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R (2009) A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15-34th ESMO Multidisciplinary Congress-Proffered Paper sessions 7(3):12
8. Stopeck A, Body JJ, Fujiwara Y, Lipton A, Steger GG, Viniegra M, Fan M, Braun A, Dansey R, Jun S (2009) Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study. European Journal of Cancer Supplements, Vol 7, Issue 3, Joint ECCO 15-34th ESMO Multidisciplinary Congress-Presidential session II 7(3):2-3
9. K Vahtsevanos A Kyrgidis E Verrou E Katodritou S Triaridis C Andreadis I Boukovinas G Koloutsos Z Teleioudis K Kitikidou P Paraskevopoulos K Zervas K Antoniades 2009 Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw J Clin Oncol 27 5356 5362 1:CAS:528:DC%2BD1MXhsFKkt7rF 10.1200/JCO.2009.21.9584 19805682
10. LM Hess JM Jeter M Benham-Hutchins DS Alberts 2008 Factors associated with osteonecrosis of the jaw among bisphosphonate users Am J Med 121 475-483 e473
11. A Kyrgidis K Vahtsevanos 2009 Osteonecrosis of the jaw in patients receiving oral bisphosphonates Osteoporos Int 10.1007/s00198-009-01089-5 19862464
12. A Kyrgidis K Vahtsevanos 2009 "Fatigue" having a role in the pathogenesis of osteonecrosis of the jaws Clin Oral Investig 13 479 480 10.1007/s00784-009-0319-8 19680698